Concepedia

Enis Aboalhasan

EA

Statistics

Publications

6

Citations

111

H-Index

6

Active since

2020

Affiliations

Tel Aviv University(Current)

Sapir College

Clalit Health Services

Maccabi Healthcare Services

Enis Aboalhasan is an author at Tel Aviv University specializing in pharmacotherapy, pharmacy, and clinical pharmacology.

ORCID

Publications per year

2020–2023

6

Publications

6

Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis

Joseph Azuri, Ariel Hammerman, Enis Aboalhasan et al. · Diabetes Obesity and Metabolism · 2022 · 41 citations · Full text

, , +17

Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis

Joseph Azuri, Ariel Hammerman, Enis Aboalhasan et al. · Obesity · 2023 · 24 citations · Full text

, , +17

Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman et al. · The American Journal of Cardiology · 2021 · 14 citations

, , +12

Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman et al. · European Journal of Preventive Cardiology · 2020 · 12 citations

, , +17

Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman et al. · The American Journal of Medicine · 2021 · 10 citations

, , +15

1–5 of 6